Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L31 pseudogene 54 (RPL31P54) is a processed pseudogene related to the ribosomal protein L31 gene (RPL31). Pseudogenes are DNA sequences similar to normal genes but generally non-functional due to mutations or lack of regulatory elements. RPL31P54 is not known to encode a protein or to be involved directly in human disease nor to represent a classical drug target. While pseudogenes can sometimes have regulatory roles (e.g., as non-coding RNAs), there is no evidence that RPL31P54 is implicated in any pathology or therapeutic intervention. It should not be confused with the functional gene RPL31, which encodes a component of the ribosomal 60S subunit, critical for protein synthesis[3][5][7].\n\nRPL31P54 is cataloged as a pseudogene by the HUGO Gene Nomenclature Committee and scientific databases, and is not considered a therapeutic target[5]. There is no published evidence of its role in drug response, biomarker utility, or involvement in any pathway subject to therapeutic modulation.\n\nRPL31P54 should not be referred to as a protein, receptor, enzyme, transporter, or classical molecular target.\n\n**Notes:**\n- Pseudogenes (including RPL31P54) are often included in genome annotation for completeness, but are infrequently targets of drug discovery or clinical diagnostics.\n- Catalog entries for RPL31P54 list aliases, confirm its non-coding (pseudogene) status, and do not assign disease or drug associations[5].\n- There is no evidence of a disease or regulatory role specific to RPL31P54 as for some other ribosomal protein pseudogenes[2].\n\nThis entry (RPL31P54) is not a correct or actionable therapeutic target and is only relevant for genomic annotation or, possibly, non-coding RNA research.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L31 pseudogene 54 (RPL31P54).